首页> 美国卫生研究院文献>other >Integrative genomic analysis identifies the core transcriptional hallmarks of human hepatocellular carcinoma Running title: Transcriptional hallmarks of liver cancer
【2h】

Integrative genomic analysis identifies the core transcriptional hallmarks of human hepatocellular carcinoma Running title: Transcriptional hallmarks of liver cancer

机译:整合基因组分析确定人类肝细胞癌的核心转录特征标题:肝癌的转录特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Integrative genomics helped characterize molecular heterogeneity in HCC, leading to targeted drug candidates for specific HCC subtypes. However, no consensus was achieved for genes and pathways commonly altered in HCC. Here we performed a meta-analysis of 15 independent datasets (n=784 human HCC) and identified a comprehensive signature consisting of 935 genes commonly deregulated in HCC as compared to the surrounding non-tumor tissue. In the HCC signature, up-regulated genes were linked to early genomic alterations in hepatocarcinogenesis, particularly gains of 1q and 8q. The HCC signature covered well-established cancer hallmarks, such as proliferation, metabolic reprogramming, and microenvironment remodeling, together with specific hallmarks associated with protein turnover and epigenetics. Subsequently, the HCC signature enabled us to assess the efficacy of signature-relevant drug candidates, including histone deacetylase inhibitors that specifically reduced the viability of six human HCC cell lines. Overall, this integrative genomics approach identified cancer hallmarks recurrently altered in human HCC that may be targeted by specific drugs. Combined therapies targeting common and subtype-specific cancer networks may represent a relevant therapeutic strategy in liver cancer.
机译:整合基因组学有助于表征HCC中的分子异质性,从而导致针对特定HCC亚型的靶向药物候选物。然而,对于肝癌中通常改变的基因和途径尚未达成共识。在这里,我们对15个独立的数据集(n = 784个人HCC)进行了荟萃分析,并确定了由935个与周围的非肿瘤组织相比通常在HCC中失活的基因组成的综合特征。在HCC签名中,上调的基因与肝癌发生中的早期基因组改变有关,尤其是1q和8q。 HCC签名涵盖了公认的癌症标志,例如增殖,代谢重编程和微环境重塑,以及与蛋白质更新和表观遗传学相关的特定标志。随后,HCC签名使我们能够评估与签名相关的候选药物的功效,其中包括组蛋白脱乙酰基酶抑制剂,这些抑制剂会特异性降低六种人类HCC细胞系的活力。总体而言,这种综合基因组学方法确定了人类HCC中反复改变的癌症标志,这些标志可能是特定药物靶向的。针对常见和亚型特异性癌症网络的联合疗法可能代表了肝癌的相关治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号